Lingyu Ding | Oncology | Distinguished Scientist Award

Published on by Health Scientists

Mrs. Lingyu Ding | Oncology | Distinguished Scientist Award

clinical nurse | Jiangsu province hospital | China

Lingyu Ding is a distinguished registered nurse at the Colorectal Surgery Department of The First Affiliated Hospital with Nanjing Medical University, specializing in oncology nursing, perioperative rehabilitation, and cancer-related frailty. She has made significant contributions to the development and validation of frailty assessment models for cancer survivors and has designed and pilot-tested multimodal interventions to manage frailty, demonstrating a strong commitment to improving patient outcomes. Her research has been published extensively in peer-reviewed journals, encompassing systematic reviews, meta-analyses, and observational studies that explore preoperative frailty, sedentary behavior, handgrip strength asymmetry, and postoperative outcomes among older adults with cancer. Lingyu has successfully secured and led a project funded by the National Natural Science Foundation of China, reflecting her leadership and research capabilities, and she actively engages in collaborative projects with multidisciplinary teams. Her work has been recognized with prestigious awards for excellence in professional practice, innovative nursing interventions, and outstanding young talent, underscoring both her academic and clinical impact. Beyond her research, Lingyu contributes to the scholarly community as a peer reviewer for international journals, ensuring the rigor and quality of scientific publications. Her expertise spans both quantitative and qualitative research methodologies, including randomized controlled trials, questionnaire design, phenomenological research, and grounded theory, complemented by proficiency in statistical analysis and academic writing. Through her clinical practice, research, and scholarly activities, Lingyu Ding advances the understanding and management of frailty in cancer patients, bridging the gap between evidence-based research and practical healthcare applications, and making a meaningful impact on patient care, health outcomes, and the broader field of oncology nursing. She has 361 citations from 33 documents with an h-index of 11.

Profile: Scopus 

Featured Publications

1. Willingness, preference, and resistance to frailty intervention for older gastric cancer based on stakeholder perspective: A qualitative study. (2025). BMC Geriatrics. Open access.

2. Clinical characteristics and correlation between preoperative frailty and metabolic syndrome among older patients with gastric cancer. (2025). Chinese General Practice.

3.BMI trajectories, associations with outcomes and predictors in elderly gastric cancer patients undergoing radical gastrectomy: A prospective longitudinal observation study. (2025). Journal of Cancer Survivorship.

Rasha Elsabagh | Oncology | Research Excellence Award

Published on by Health Scientists

Dr. Rasha Elsabagh | Oncology | Research Excellence Award

Researcher | Animal Health Research Institute(AHRI) | Egypt

Rasha H. Elsabagh is a multidisciplinary immunology specialist and cancer stem cell researcher with extensive expertise spanning stem cell biology, immuno-oncology, translational cancer research, and veterinary biomedical sciences. She currently serves as a researcher at the Animal Health Research Institute, where her work integrates advanced immunological diagnostics, molecular biology, and national livestock immunization programs that directly contribute to animal health surveillance and disease control. Her academic training culminated in a doctoral degree in cancer immunology from Cairo University, where her research focused on circulating cancer stem cells and photothermal nanotherapy as predictive and monitoring tools for tumor response. She has conducted advanced international research training at University of California San Francisco, gaining high-level proficiency in flow cytometry, immunofluorescence, and human stem cell analysis, and later expanded her translational oncology experience as a visiting research fellow at the Cancer Institute of Montpellier, working on nanoparticle-mediated RNA delivery to tumor-infiltrating immune cells. Her scientific output includes multiple peer-reviewed publications in high-impact journals and international conference proceedings, with her work receiving sustained scholarly citations and global academic recognition. Her research collaborations span institutions in North America, Europe, and the Middle East, reflecting her active role in international scientific networks in stem cell biology, cancer immunology, and nanomedicine. Beyond laboratory research, she contributes to national capacity building through scientific training, quality assurance in diagnostic immunology, and public health–oriented animal disease control programs. Her work has direct societal impact through improvements in cancer diagnostics, advancement of immunotherapeutic strategies, and strengthening of zoonotic disease surveillance, positioning her as a globally engaged scientist at the intersection of experimental research, translational medicine, and public health. She has 2 citations from 2 documents with an h-index of 1.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Xiao, T., Eze, U. C., Charruyer-Reinwald, A., Weisenberger, T., Khalifa, A., … (2024). Short cell cycle duration is a phenotype of human epidermal stem cells. Stem Cell Research & Therapy, 15(1), 76.

2. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Ragab, E., … (2021). Quantitative flow cytometry assessment of feline circulatory breast cancer stem cells. Advances in Animal and Veterinary Sciences, 9(12), 2201–2215.

3. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H. H., Ragab, E., … (2025). Gold nano-rod (AuNR)-mediated plasmonic photothermal therapy in feline mammary carcinoma: Assessing metastatic and nonmetastatic outcomes. Veterinary Oncology, 2(1), 33.

4. Elsabagh, R. H., Farghali, H. A. M., Emam, I. A., Abdelrahman, H., Ragab, E., … (2022). Prevention of in situ recurrence and distant metastasis in feline mammary carcinoma treated with plasmonic photothermal therapy.

 

Huiling Chen | Oncology | Best Researcher Award

Published on by Health Scientists

Dr. Huiling Chen | Oncology | Best Researcher Award 

Physician | Lanzhou University | China

Dr. Huiling Chen is a distinguished physician and researcher at The Second Hospital and Clinical Medical School, Lanzhou University, recognized for her significant contributions to the field of hematologic malignancies, particularly acute myeloid leukemia (AML). Her research primarily focuses on advancing evidence-based therapeutic strategies through systematic reviews and meta-analyses that inform clinical decision-making and improve patient outcomes. As the lead investigator and corresponding author of a comprehensive meta-analysis published in the Annals of Hematology, Dr. Chen evaluated the efficacy and safety of venetoclax plus azacitidine regimens in relapsed or refractory AML, providing vital insights into their clinical utility and identifying combination chemotherapy as a promising approach for improving remission outcomes. Her expertise lies in clinical epidemiology, biostatistics, and the design and interpretation of complex data in oncology research. Through collaborations with multidisciplinary teams across national and international institutions, she has contributed to multicenter studies that bridge gaps between clinical research and real-world applications. Her scholarly work exemplifies a commitment to scientific rigor, innovation, and translational relevance, with her findings influencing the direction of future clinical trials and treatment paradigms for high-risk AML populations. Dr. Chen’s research efforts aim to optimize therapeutic interventions, enhance personalized treatment planning, and advance precision medicine in hematology. Beyond her academic accomplishments, she upholds a strong dedication to mentoring and fostering collaborative research environments that encourage cross-institutional partnerships and scientific dialogue. Her contributions embody the integration of analytical excellence, clinical insight, and humanitarian vision, underscoring her role as a leader shaping the future of hematologic cancer research and its impact on global health.

Profile: ORCID 

Featured Publications

1. Chen, H., Li, X., Gao, L., Zhang, D., & Han, T. (2022, August). Construction and identification of an immortalized rat intestinal smooth muscle cell line. Neurogastroenterology & Motility.

2. Chen, H., Ren, X., Xu, S., Zhang, D., & Han, T. (2022, July). Optimization of lipid nanoformulations for effective mRNA delivery. International Journal of Nanomedicine.

3. Chen, H., Han, T., Gao, L., & Zhang, D. (2022, January). The involvement of glial cell-derived neurotrophic factor in inflammatory bowel disease. Journal of Interferon & Cytokine Research.

4. Chen, H., Zeng, P., & Zhang, D. (2020, February). Haemophagocytic syndrome triggered by acute lymphoblastic leukaemia with t(9;22)(p24; q11.2). Journal of International Medical Research.